KR20030051753A - 레닌 저해제를 포함하는 심장혈관 질환용 상승효과배합물 - Google Patents

레닌 저해제를 포함하는 심장혈관 질환용 상승효과배합물 Download PDF

Info

Publication number
KR20030051753A
KR20030051753A KR10-2003-7005901A KR20037005901A KR20030051753A KR 20030051753 A KR20030051753 A KR 20030051753A KR 20037005901 A KR20037005901 A KR 20037005901A KR 20030051753 A KR20030051753 A KR 20030051753A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
hypertension
acceptable salts
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2003-7005901A
Other languages
English (en)
Korean (ko)
Inventor
헤위트윌리암
바셀라다니엘루시우스
웹랜디리
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20030051753(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20030051753A publication Critical patent/KR20030051753A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
KR10-2003-7005901A 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과배합물 Ceased KR20030051753A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds
GB0028151.9 2000-11-17
PCT/EP2001/013241 WO2002040007A1 (en) 2000-11-17 2001-11-15 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087001407A Division KR20080011355A (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물

Publications (1)

Publication Number Publication Date
KR20030051753A true KR20030051753A (ko) 2003-06-25

Family

ID=9903412

Family Applications (6)

Application Number Title Priority Date Filing Date
KR10-2003-7005901A Ceased KR20030051753A (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과배합물
KR1020107018819A Ceased KR20100114904A (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
KR1020087024051A Withdrawn KR20080096715A (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
KR1020087001407A Ceased KR20080011355A (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
KR1020087024052A Expired - Fee Related KR101008752B1 (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
KR1020117012347A Expired - Fee Related KR101258365B1 (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020107018819A Ceased KR20100114904A (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
KR1020087024051A Withdrawn KR20080096715A (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
KR1020087001407A Ceased KR20080011355A (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
KR1020087024052A Expired - Fee Related KR101008752B1 (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
KR1020117012347A Expired - Fee Related KR101258365B1 (ko) 2000-11-17 2001-11-15 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물

Country Status (31)

Country Link
US (4) US8168616B1 (https=)
EP (7) EP1602370B1 (https=)
JP (6) JP2004513920A (https=)
KR (6) KR20030051753A (https=)
CN (4) CN100404024C (https=)
AT (2) ATE317692T1 (https=)
AU (2) AU2002223680B2 (https=)
BR (1) BR0115411A (https=)
CA (2) CA2428647A1 (https=)
CY (5) CY1105603T1 (https=)
CZ (2) CZ299749B6 (https=)
DE (3) DE60134349D1 (https=)
DK (3) DK1341533T3 (https=)
EC (1) ECSP034603A (https=)
ES (4) ES2429292T3 (https=)
GB (1) GB0028151D0 (https=)
HU (2) HU230882B1 (https=)
IL (3) IL155707A (https=)
LU (2) LU91563I2 (https=)
MX (1) MXPA03004358A (https=)
NL (2) NL300385I1 (https=)
NO (2) NO334002B1 (https=)
NZ (6) NZ537691A (https=)
PL (3) PL400915A1 (https=)
PT (3) PT1341533E (https=)
RU (2) RU2310443C2 (https=)
SG (1) SG135969A1 (https=)
SI (3) SI1915993T1 (https=)
SK (1) SK287881B6 (https=)
WO (1) WO2002040007A1 (https=)
ZA (1) ZA200303497B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005509631A (ja) * 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
BR0310084A (pt) 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
CA2490811A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
JP4884230B2 (ja) 2003-11-26 2012-02-29 ノバルティス アーゲー 有機化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
ATE472524T1 (de) * 2004-01-23 2010-07-15 Novartis Ag Diaminoalkohole und deren verwendung als renininhibitoren
EP1711456A2 (en) * 2004-01-23 2006-10-18 Speedel Experimenta AG Amino alcohol derivatives and their use as renin inhibitors
BRPI0506491A (pt) * 2004-01-23 2007-02-13 Speedel Experimenta Ag compostos orgánicos
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
ES2384637T3 (es) * 2004-10-08 2012-07-10 Novartis Ag Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
US20090247582A1 (en) * 2005-04-27 2009-10-01 Randy Lee Webb Methods of treating atherosclerosis
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
DE602005005706T2 (de) * 2005-09-28 2009-04-16 Teva Pharmaceutical Industries Ltd. Stabile Arzneimittelkombinationen von Amlodipinbesylat und Benazeprilhydrochlorid
KR20080066776A (ko) * 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
US20100029775A1 (en) * 2006-12-15 2010-02-04 Prescott Margaret F Renin inhibitors for the prevention and treatment of hypertension in obese patients
US20080194626A1 (en) * 2007-02-14 2008-08-14 Gorczynski Richard J Antihypertensive drug combination
US20100209480A1 (en) * 2007-09-28 2010-08-19 Ralf Altenburger Galenical formulations of organic compounds
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
WO2009104939A2 (ko) 2008-02-22 2009-08-27 한올제약주식회사 약제학적 제제
US20110111022A1 (en) 2008-04-10 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical formulation
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
KR101209319B1 (ko) 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2189442B1 (en) 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
EP2408427A1 (en) 2009-03-20 2012-01-25 Novartis AG Galenical formulations of a fixed dose combination of valsartan and aliskiren
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2704706A1 (en) 2011-05-06 2014-03-12 Artskin D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
EP3682902A1 (en) * 2012-05-18 2020-07-22 Luoda Pharma Limited Liquid formulation
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
DK3174530T3 (en) 2014-07-30 2018-11-26 Merck Patent Gmbh DIRECT COMPATIBLE POLYVINYL ALCOHOLS
KR102923585B1 (ko) * 2016-10-27 2026-02-04 다미안 파르마 에이쥐 알도스테론 합성효소 저해제

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
DK0403159T3 (da) 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
TW201738B (https=) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DK0527879T3 (da) * 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
CA2089268A1 (en) * 1990-08-15 1992-02-16 William R. Baker Renin inhibitors
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
KR100222252B1 (ko) * 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
AU1256692A (en) 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (https=) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0699069B9 (en) 1993-04-27 2003-10-22 Smithkline Beecham Corporation Endothelin receptor antagonists
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
PT634175E (pt) * 1993-07-15 2001-06-29 Hoffmann La Roche Combinacao farmaceutica que contem um inibidor do sistema renina-angiotensina e o antagonista de endotelina
AU675870B2 (en) 1993-08-18 1997-02-20 Msd K.K. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
WO1996006095A1 (en) 1994-08-19 1996-02-29 Abbott Laboratories Endothelin antagonists
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (https=) 1994-12-20 1997-08-21 Hoffmann La Roche
PL184060B1 (pl) 1995-01-27 2002-08-30 Rhone Poulenc Rorer Ltd Podstawione związki fenylowe do zastosowania jako środki antagonistyczne endoteliny
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
JP3087968B2 (ja) 1995-12-20 2000-09-18 山之内製薬株式会社 アリールエテンスルホンアミド誘導体及びその医薬組成物
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
EP0906108B1 (en) 1996-04-04 2005-06-15 Banyu Pharmaceutical Co., Ltd. Endothelin antagonists for treating heart failure
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
AU750122C (en) * 1998-06-17 2003-02-27 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination
NZ509378A (en) 1998-07-20 2003-04-29 Smithkline Beecham Corp Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CA2368187A1 (en) * 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
CA2390561A1 (en) 1999-11-09 2001-05-17 Pharmacia Corporation Use of an aldosterone antagonist for treating restenosis
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
BR0310084A (pt) 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
ATE397147T1 (de) 2002-12-31 2008-06-15 Volkswagen Ag Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine

Also Published As

Publication number Publication date
RU2310443C2 (ru) 2007-11-20
DE122009000021I1 (de) 2009-08-06
JP2017019876A (ja) 2017-01-26
NO334002B1 (no) 2013-11-11
HK1059212A1 (en) 2004-06-25
SK5842003A3 (en) 2003-11-04
KR101258365B1 (ko) 2013-04-30
DK1915993T3 (da) 2013-10-14
SI1341533T1 (sl) 2006-08-31
CY1105603T1 (el) 2010-07-28
NO20032233L (no) 2003-05-16
US8168616B1 (en) 2012-05-01
SI1915993T1 (sl) 2013-10-30
EP2305231A1 (en) 2011-04-06
RU2346703C2 (ru) 2009-02-20
JP6603757B2 (ja) 2019-11-06
EP1602370A3 (en) 2005-12-14
IL217847A0 (en) 2012-03-29
HU1400409D0 (hu) 2003-09-29
MXPA03004358A (es) 2003-08-19
CZ299749B6 (cs) 2008-11-12
NZ525795A (en) 2005-03-24
PL361404A1 (en) 2004-10-04
EP1602370A2 (en) 2005-12-07
JP2018030894A (ja) 2018-03-01
HUP0301841A2 (hu) 2003-09-29
DE60117295D1 (de) 2006-04-20
CN1474690A (zh) 2004-02-11
IL155707A0 (en) 2003-11-23
US9023893B2 (en) 2015-05-05
KR20080011355A (ko) 2008-02-01
CY2013045I2 (el) 2015-11-04
US20120010295A1 (en) 2012-01-12
NL301005I2 (nl) 2019-10-29
LU92315I2 (fr) 2014-01-27
ATE317692T1 (de) 2006-03-15
SI1602370T1 (sl) 2008-10-31
KR20080096715A (ko) 2008-10-31
CA2763223A1 (en) 2002-05-23
EP1930000A1 (en) 2008-06-11
DK1602370T3 (da) 2008-09-22
ECSP034603A (es) 2003-06-25
ES2308347T3 (es) 2008-12-01
EP2305233A1 (en) 2011-04-06
PT1602370E (pt) 2008-09-10
ATE397445T1 (de) 2008-06-15
IL212075A (en) 2013-08-29
IL155707A (en) 2012-02-29
CA2428647A1 (en) 2002-05-23
IL212075A0 (en) 2011-06-30
NZ550897A (en) 2008-03-28
KR20110063596A (ko) 2011-06-10
NL300385I1 (nl) 2009-07-01
CZ305341B6 (cs) 2015-08-05
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
US8618174B2 (en) 2013-12-31
BR0115411A (pt) 2004-08-17
WO2002040007A1 (en) 2002-05-23
KR20100114904A (ko) 2010-10-26
JP2018131465A (ja) 2018-08-23
RU2006132668A (ru) 2008-03-20
NZ537691A (en) 2007-01-26
NO2013019I2 (no) 2013-12-17
JP2004513920A (ja) 2004-05-13
EP1341533A1 (en) 2003-09-10
PL400915A1 (pl) 2012-12-17
AU2002223680B2 (en) 2005-04-07
CY1108305T1 (el) 2012-01-25
JP2013213061A (ja) 2013-10-17
NL301005I1 (https=) 2019-09-10
NZ550898A (en) 2008-07-31
CN101091703A (zh) 2007-12-26
US9023894B2 (en) 2015-05-05
DK1341533T3 (da) 2006-05-08
US20120016035A1 (en) 2012-01-19
NO2013019I1 (no) 2014-06-02
KR20080097488A (ko) 2008-11-05
GB0028151D0 (en) 2001-01-03
CY2009005I2 (el) 2012-01-25
JP6373931B2 (ja) 2018-08-15
EP2305232B1 (en) 2019-07-17
JP6089278B2 (ja) 2017-03-08
DE60134349D1 (de) 2008-07-17
ZA200303497B (en) 2004-04-28
ES2429292T3 (es) 2013-11-14
EP1341533B1 (en) 2006-02-15
PL227576B1 (pl) 2017-12-29
CY2009005I1 (el) 2012-01-25
US20120004312A1 (en) 2012-01-05
ES2734523T3 (es) 2019-12-10
CN101264073A (zh) 2008-09-17
HUP0301841A3 (en) 2010-07-28
HU230882B1 (hu) 2018-11-29
HK1115544A1 (en) 2008-12-05
HK1089356A1 (en) 2006-12-01
CY1114829T1 (el) 2015-11-04
KR101008752B1 (ko) 2011-01-14
DE60117295T2 (de) 2006-08-17
ES2256335T3 (es) 2006-07-16
JP2009235107A (ja) 2009-10-15
EP2305232A1 (en) 2011-04-06
CY2013045I1 (el) 2015-11-04
CN100404024C (zh) 2008-07-23
EP1602370B1 (en) 2008-06-04
SK287881B6 (sk) 2012-02-03
EP1915993B1 (en) 2013-07-10
CN101264072A (zh) 2008-09-17
PT1341533E (pt) 2006-06-30
NO20032233D0 (no) 2003-05-16
JP6577994B2 (ja) 2019-09-18
PL400914A1 (pl) 2012-12-17
AU2368002A (en) 2002-05-27
LU91563I2 (fr) 2009-07-06
SG135969A1 (en) 2007-10-29
NZ568764A (en) 2009-11-27
EP1915993A1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
KR101258365B1 (ko) 레닌 저해제를 포함하는 심장혈관 질환용 상승효과 배합물
AU2002223680A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
HK1116699A (en) Combination of organic compounds
HK1155357A (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
HK1155093A (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
HK1155097B (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030428

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20061107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071031

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080117

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080508

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071031

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080808

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080508

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20090630

Appeal identifier: 2008101007885

Request date: 20080808

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080908

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080808

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080117

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20061107

Patent event code: PB09011R02I

E801 Decision on dismissal of amendment
PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20081008

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080908

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080117

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20061107

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080808

Effective date: 20090630

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20090630

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20080808

Decision date: 20090630

Appeal identifier: 2008101007885

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20090630

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100716

Appeal identifier: 2009201006519

Request date: 20090904

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090904

Effective date: 20100716

PJ1302 Judgment (patent court)

Patent event date: 20100722

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20090904

Decision date: 20100716

Appeal identifier: 2009201006519

Appeal kind category: Appeal against decision to decline refusal

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20100802

WITB Written withdrawal of application
J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20100804

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2008101007885

Request date: 20080808

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20090630